Long intergenic non-coding adipose anti-inflammatory (LINC-ADAIN)

LINC-ADAIN (long intergenic non-coding adipose anti-inflammatory) is a human lincRNA whose expression is reduced in the white adipose tissue of obese individuals. Its depletion increases the stability and translation of KLF5 and IL-8 mRNAs by interacting with IGF2BP2, leading to enhanced adipogenic programs and increased local inflammation, which mirror obesity-induced adipose tissue dysfunction. LINC-ADAIN acts as a suppressor of adipose tissue expansion, lipid storage, and inflammation; thus, it may be important in limiting the development of obesity-related metabolic complications such as insulin resistance, type 2 diabetes, and cardiovascular disease. LINC-ADAIN is part of the emerging class of regulatory RNAs in metabolism, distinct from known protein-coding adipokines. It acts via post-transcriptional regulation of major inflammatory and adipogenesis-related genes (notably KLF5 and IL-8) and directly interacts with the mRNA-binding protein IGF2BP2. No evidence in current literature links LINC-ADAIN to direct drug targeting or pharmaceutical interventions.

Other names

LINC-DMRT2lnc-DMRT2LINC01230TCONS_00015639Linc-ADAIN